Signal
Sanofi pays $180 million for rights to Kali Therapeutics' phase 1 trispecific antibody
Sanofi has re-entered the T-cell engager space by securing rights to a phase 1-stage trispecific antibody from Kali Therapeutics. The deal involves an upfront payment of $180 million, marking Sanofi's renewed focus on autoimmune drug development through this promising candidate.
rss
clinical_trialsbiotech_fundingdrug_development
Evidence locked
Today's free sample is only available for the edition's flagship signal.
Evidence preview
- Sanofi pays $180m for rights to Kali autoimmune drug - pharmaphorumpharmaphorum.com
- Sanofi returns to T-cell engager territory with $180M deal for Kali trispecific...fiercebiotech.com